1Luckie M, Khattar R. Paradoxical systolic and diastolic flow ab- normalities in hypertrophic cardiomyopathy with mid-cavity systol- ic obstruction. Cardiol J,2011,18:314-317.
3Marian AJ. Genetic determinants of cardiac Hypertrophy. Curr Opin Cardiol, 2008,23 : 199-205.
4Tanjore R,Rangaraju A, Vadapalli S,et al. Genetic variations of β-MYH7 in hypertrophic cardiomyopathy and dilated cardiomyop- athy. Indian J Hum Genet,2010 ,16 :67-71.
5Rosing DR, Kent KM, Borer JS, et al. Verapamil therpy: a new sp- proach to pharmacologyic treatment of hypertrophic cardiomyopa- thy hemodynamic effects. Circulation, 1997,60 : 1202-1207.
6Carasso S, Yang H, Woo A, et al.Diastolic myocardial mechanics in hypertrophic cardiomyopathy. J Am Soc Echocardiogr, 2010, 23:164-171.
7Zou YB, Song L, Wang ZM, et al. Prevalence of idiopathic hyper- trophic cardiomyopathy in China:A population-based echocardio- graphic analysis of 8080 adults. Am J Med ,2004,116 : 14-18.
8Gersh B J, Maron B J, Bonow RO, et al. 2011 ACCF/AHA guide- line for the diagnosis and treatment of hypertrophic cardiomyopa- thy:executive summary:a report of the American College of Car- diology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation ,2011,124:783-831.
9Cohen LS,Braunwald E. Amelioration of angina pectoris in idio- pathic hypertrophic subaortic stenosis with beta-adrenergic block- ade. Cirulation, 1967,35 : 847-851.
10Sigwart U. Non-surgical myocardial reduction for hypertropic ob- structive eardiomyopathy. Lancet, 1995,346:211-214.
